Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | IAPP | P10997 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | DDO | Q99489 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951885 | 1.00 | GABRA1 (0.52) | GABRA1GABRB2ERN1IAPPCA1 | |
| SCHEMBL7090370 | 0.91 | GABRA1 (0.44) | GABRA1GABRB2ERN1IAPPCA1 | |
| SCHEMBL1527068 | 0.86 | IAPP (0.44) | GABRA1GABRB2IAPP | |
| SCHEMBL5429057 | 0.85 | HSPA5 (0.50) | GABRA1GABRB2ERN1CA1CA2 | |
| SCHEMBL320588 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2 | |
| SCHEMBL1527069 | 0.83 | BID (0.50) | IAPPTSHR | |
| SCHEMBL11771453 | 0.83 | GABRA1 (0.52) | GABRA1GABRB2IAPPCA1CA2 | |
| SCHEMBL4709719 | 0.83 | ERN1 (0.46) | GABRA1GABRB2ERN1CA2TRIM24 | |
| SCHEMBL1527143 | 0.82 | BID (0.56) | IAPP | |
| SCHEMBL4390000 | 0.82 | ERN1 (0.41) | GABRA1GABRB2ERN1IAPPCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108365194-B | Preparation method of composite negative electrode material for lithium ion battery | 深圳市普锐能源科技有限公司 | 2020-02-14 | — | — | CN | claimed |
| JP-4587669-B2 | — | — | 2010-11-24 | — | — | JP | claimed |
| JP-2005509662-A | — | — | 2005-04-14 | — | — | JP | claimed |
| CN-1589136-A | Pharmaceutical and cosmetic compositions containing aromatic aldehydes bearing oxygen-containing groups | CUTANIX CORP (US) | 2005-03-02 | — | — | CN | claimed |
| EP-1443915-A1 | PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES | Cutanix Corporation (US) | 2004-08-11 | — | — | EP | claimed |
| US-20030157154-A1 | Compositions containing hydroxy aromatic aldehydes and their use in treatments | CUTANIX CORPORATION | 2003-08-21 | — | — | US | claimed |
| WO-2003043621-A1 | PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES | CUTANIX CORPORATION (US) | 2003-05-30 | — | — | WO | claimed |
| CN-108365194-B | Preparation method of composite negative electrode material for lithium ion battery | 深圳市普锐能源科技有限公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-3265439-B1 | PROCESS FOR PREPARING 3-CHLORO-2-VINYLPHENYLSULFONATES | BAYER CROPSCIENCE AG (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2001016232-A1 | COPOLYESTER ELASTOMER COMPOSITIONS AND FUSION BONDED ARTICLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5443867-A | Heterogenous melt of polyolefin, a barrier resin consists of blend of condensation polymer incompatible with polyolefin such as polyamide and polyester, a phenol-formaldehyde resin and a compatibilizer | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-08-22 | — | — | US | disclosed |
| WO-1995011939-A2 | ARTICLES INCORPORATING BARRIER RESINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-05-04 | — | — | WO | disclosed |
| US-4122256-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4052433-A | INTERMEDIATES FOR BENZOFURANS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-4002423-A | Benzofuran derivatives process for their preparation and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
| US-3994879-A | CONDENSING AZOMETHINES, OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157154-A1 | Compositions containing hydroxy aromatic aldehydes and their use in treatments | TYR, HRH1, HRH2 | GABRA1 2542/4885GABRB2 2192/4885ERN1 4830/4885 |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | GABRA1 3561/4885GABRB2 3580/4885ERN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.